This clinical trial is focused on studying a condition called Multifocal Motor Neuropathy (MMN). MMN is a rare disorder that affects the nerves, leading to muscle weakness, especially in the arms and hands. The study will evaluate a new treatment called DNTH103, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins designed to target specific parts of the immune system. In this study, DNTH103 will be given as a solution for injection, either through a vein (intravenous) or under the skin (subcutaneous).

The purpose of the study is to assess the safety and tolerability of DNTH103 in adults with MMN. Participants will be randomly assigned to receive either DNTH103 or a matching placebo. The study will be conducted in a double-blinded manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last up to 17 weeks, during which participants will be closely monitored for any side effects and changes in their condition.

Throughout the study, various assessments will be conducted to evaluate the effects of DNTH103. These assessments will include measuring grip strength, monitoring any changes in the participants’ ability to perform daily activities, and tracking any adverse events that may occur. The study aims to provide valuable information on the potential benefits and risks of DNTH103 for individuals with MMN.